Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer

Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established...

Full description

Saved in:

Bibliographic Details
Published in:	Oncogene Vol. 31; no. 17; pp. 2153 - 2163
Main Authors:	Urbanucci, A, Sahu, B, Seppälä, J, Larjo, A, Latonen, L M, Waltering, K K, Tammela, T L J, Vessella, R L, Lähdesmäki, H, Jänne, O A, Visakorpi, T
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 26-04-2012 Nature Publishing Group
Subjects:	Androgen receptors Androgens Animals Apoptosis Binding Sites Castration Cell Biology Cell Line, Tumor Chromatin Chromatin - metabolism Data processing Endonuclease FEN1 protein Flap Endonucleases - genetics Gene Amplification Gene expression Gene Expression Profiling Genetic aspects Hormone receptors Human Genetics Humans Immunoprecipitation Internal Medicine Intracellular Signaling Peptides and Proteins - genetics Kinases Male Medicine Medicine & Public Health Mice Nuclear Proteins - genetics Nucleic Acid Amplification Techniques Oncology original-article Pheochromocytoma cells Physiological aspects Prognosis Prostate cancer Prostatectomy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Receptors, Androgen - genetics Receptors, Androgen - metabolism Risk factors S-Phase Kinase-Associated Proteins - genetics Signal transduction siRNA Snail protein Transplantation, Heterologous Xenografts Finland ChIP-seq AR prostatic neoplasia FEN1 SKP2 ZWINT
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established two sublines of LNCaP prostate cancer (PC) cell line, one overexpressing AR 2–3-fold and the other 4–5-fold compared with the control cells. We used chromatin immunoprecipitation (ChIP) and deep-sequencing (seq) to identify AR-binding sites (ARBSs). We found that the number of ARBSs and the AR-binding strength were positively associated with the level of AR when cells were stimulated with low concentrations of androgens. In cells overexpressing AR, the chromatin binding of the receptor took place in 100-fold lower concentration of the ligand than in control cells. We confirmed the association of AR level and chromatin binding in two PC xenografts, one containing AR gene amplification with high AR expression, and the other with low expression. By combining the ChIP-seq and expression profiling, we identified AR target genes that are upregulated in PC. Of them, the expression of ZWINT , SKP2 (S-phase kinase-associated protein 2 (p45)) and FEN1 (flap structure-specific endonuclease 1) was demonstrated to be increased in CRPC, while the expression of SNAI2 was decreased in both PC and CRPC. FEN1 protein expression was also associated with poor prognosis in prostatectomy-treated patients. Finally, the knock-down of FEN1 with small interfering RNA inhibited the growth of LNCaP cells. Our data demonstrate that the overexpression of AR sensitizes the receptor binding to chromatin, thus, explaining how AR signaling pathway is reactivated in CRPC cells.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0950-9232 1476-5594
DOI:	10.1038/onc.2011.401